Could this pill protect kidneys in diabetes?
NCT ID NCT07496177
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests whether an investigational drug called HTD1801 can slow the worsening of kidney disease in adults who have both type 2 diabetes and chronic kidney disease. About 75 participants will take either HTD1801 or a placebo twice daily for 12 weeks. Researchers will measure changes in kidney function to see if the drug helps protect the kidneys.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weifang People's Hospital
RECRUITINGWeifang, Shandong, 261000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a phone app be the key to managing kidney disease?
- Can a pill tailored to inflammation boost red blood cells in kidney disease?
- New diabetes pill HRS9531 enters Mid-Stage trial – could it help control blood sugar?
- Study links gum health to rare kidney diseases
- New stem cell therapy aims to restore kidney function in early trial
- New diabetes drug HM15275 enters Mid-Stage trial